Transition from Intravenous Immunoglobulin to Efgartigimod PH20 SC in Participants with Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 4 Study in Progress

Phase 3 Trial Designs Evaluating Riliprubart, a C1s-Complement Inhibitor, in Chronic Inflammatory Demyelinating Polyneuropathy

Budget Impact of Subcutaneous Immunoglobulin, Intravenous Immunoglobulin and Efgartigimod Alfa in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the United States

Impact of Diabetes Mellitus on Clinical Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy